Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.35 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278281 | 0.91 | LMNA (0.39) | LMNAALDH1A1SMN1; SMN2RAB9AHPGD | |
| SCHEMBL19209537 | 0.86 | APOBEC3G (0.40) | LMNAEHMT2EHMT1APOBEC3GALDH1A1 | |
| SCHEMBL465750 | 0.82 | LMNA (0.37) | LMNAEHMT2EHMT1APOBEC3GALDH1A1 | |
| SCHEMBL28514925 | 0.81 | LMNA (0.45) | LMNAEHMT2EHMT1APOBEC3GALDH1A1 | |
| SCHEMBL12092095 | 0.76 | LMNA (0.42) | LMNAEHMT2EHMT1APOBEC3GALDH1A1 | |
| SCHEMBL4445539 | 0.76 | NPC1 (0.36) | LMNAEHMT2EHMT1APOBEC3GALDH1A1 | |
| SCHEMBL7112244 | 0.75 | EHMT2 (0.35) | LMNAEHMT2EHMT1APOBEC3GALDH1A1 | |
| SCHEMBL4405681 | 0.75 | GCK (0.40) | LMNAALDH1A1SMN1; SMN2RAB9AHPGD | |
| SCHEMBL42368 | 0.74 | ALDH1A1 (0.44) | LMNAEHMT2EHMT1APOBEC3GALDH1A1 | |
| SCHEMBL29352062 | 0.74 | ALDH1A1 (0.44) | LMNAEHMT2EHMT1APOBEC3GALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277863-A1 | ANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSES | HELIX BIOPHARMA CORPORATION (CA) | 2024-08-22 | — | — | US | disclosed |
| US-11931422-B2 | Antibody-urease conjugates for therapeutic purposes | HELIX BIOPHARMA CORPORATION (CA) | 2024-03-19 | — | — | US | disclosed |
| EP-3261678-B1 | ANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSES | HELIX BIOPHARMA CORP (CA) | 2020-11-11 | — | — | EP | disclosed |
| US-20180243437-A1 | ANTI-VEGFR-2 UREASE CONJUGATES | HELIX BIOPHARMA CORP. (CA) | 2018-08-30 | — | — | US | disclosed |
| WO-2018126315-A1 | ANTI-VEGFR-2 UREASE CONJUGATES | HELIX BIOPHARMA CORPORATION (CA) | 2018-07-12 | — | — | WO | disclosed |
| US-20180000963-A1 | ANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSES | HELIX BIOPHARMA CORPORATION (CA) | 2018-01-04 | — | — | US | disclosed |
| EP-3261678-A1 | ANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSES | Helix Biopharma Corp. (CA) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016116907-A1 | ANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSES | HELIX BIOPHARMA CORPORATION (CA) | 2016-07-28 | — | — | WO | disclosed |
| EP-2707384-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | Apellis Pharmaceuticals, Inc. (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8604170-B2 | Antibody against the CSF-1R | TRANSGENE S.A. (FR) | 2013-12-10 | — | — | US | disclosed |
| WO-2012155107-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20110081353-A1 | ANTIBODY AGAINST THE CSF-1 R | TRANSGENE S.A. (FR) | 2011-04-07 | — | — | US | disclosed |
| US-7354591-B2 | Poxvirus with targeted infection specificity | TRANSGENE S.A. (FR) | 2008-04-08 | — | — | US | disclosed |
| US-7348014-B2 | Poxvirus with targeted infection specificity | TRANSGENE, S.A. (FR) | 2008-03-25 | — | — | US | disclosed |
| US-20050208074-A1 | Poxvirus with targeted infection specificity | TRANSGENE S.A. (FR) | 2005-09-22 | — | — | US | disclosed |
| US-20030165477-A1 | Poxvirus with targeted infection specificity | TRANSGENE S.A. (FR) | 2003-09-04 | — | — | US | disclosed |
| WO-2000002576-A9 | EGF-GENISTEIN FOR PREVENTION OF RESTENOSIS | WAYNE HUGHES INST (US) | 2000-05-25 | — | — | WO | disclosed |
| US-6034053-A | VASCULAR DISORDERS | WAYNE HUGHES INSTITUTE (US) | 2000-03-07 | — | — | US | disclosed |
| WO-2000002576-A2 | EGF-GENISTEIN FOR PREVENTION OF RESTENOSIS | PARKER HUGHES INSTITUTE (US) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277863-A1 | ANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSES | SLC14A1, UROD, UNG | LMNA 4080/4885EHMT2 400/4885EHMT1 556/4885 |
| US-20180243437-A1 | ANTI-VEGFR-2 UREASE CONJUGATES | KDR, FLT1, FLT4 | LMNA 4733/4885EHMT2 764/4885EHMT1 2166/4885 |
| US-11931422-B2 | Antibody-urease conjugates for therapeutic purposes | SLC14A1, UNG, UPP1 | LMNA 2440/4885EHMT2 1735/4885EHMT1 1966/4885 |
| US-20180000963-A1 | ANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSES | SLC14A1, UNG, UPP1 | LMNA 2440/4885EHMT2 1735/4885EHMT1 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.